Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells

Human Gene Therapy

Volumn 10, Issue 18, 1999, Pages 2907-2916

  Arienti, Flavio ^a   Belli, Filiberto ^a   Napolitano, Filomena ^a   Sulé Suso, Josep ^a,b   Mazzocchi, Arabella ^a   Gallino, Gian Francesco ^a   Cattelan, Alessandro ^c   Sanantonio, Cristina ^c   Rivoltini, Licia ^a   Melani, Cecilia ^a   Colombo, Mario Paolo ^a   Cascinelli, Natale ^a   Maio, Michele ^c   Parmiani, Giorgio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY HOSPITALS OF NORTH MIDLANDS NHS TRUST   (United Kingdom)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 4;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOLOGY; CLINICAL ARTICLE; FEMALE; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; MELANOMA; VACCINATION;

ADULT; AGED; AUTOANTIBODIES; CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE THERAPY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERFERON TYPE II; INTERLEUKIN-4; INTERLEUKIN-6; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MELANOMA; MIDDLE AGED; TUMOR CELLS, CULTURED;

EID: 0033544933     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950016320     Document Type: Article

References (45)

1. ARIENTI, F., SULÉ-SUSO, J., MELANI, C., MACCALLI, C., BELLI, F., ILLENI, M.T., ANICHINI, A., CASCINELLI, N., COLOMBO, M.P., and PARMIANI, G. (1994). Interleukin-1 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes. Hum. Gene Ther. 5, 1139-1150.
2. ARIENTI, F., SULÉ-SUSO, J., BELLI, F., MASCHERONI, L., RIVOLTINI, L., MELANI, C., MAIO, M., CASCINELLI, N., COLOMBO, M.P., and PARMIANI, G. (1996). Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum. Gene Ther. 7, 1955-1963.
3. BOON, T., GAJEWSKI, T.F., and COULIE, P. (1995). From defined human tumor antigens to effective immunization? Immunol. Today 16, 334-336.
4. BOSCO, M.C., GIOVARELLI, M., FORNI, M., MODESTI, A., SCARPA, S., MASUELLI, L., and FORNI, G. (1990). Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory. J. Immunol. 145, 3136-3143.
5. CASCINELLI, N., FOA, R., and PARMIANI, G. (1994). Active immunization of metastatic melanoma patients with interleukin-4 transduced, allogeneic melanoma cells. A phase I-II study - clinical protocol. Hum. Gene Ther. 5, 1059-1064.
6. COLOMBO, M.P., and FORNI, G. (1994). Cytokine gene transfer in tumor inhibition and tumor therapy: Where are we now? Immunol. Today 15, 48-51.
7. CORMIER, J.N., SALGALLER, M.L., PREVETTE, T., BARRACCHINI, K.C., RIVOLTINI, L., RESTIFO, N.P., ROSENBERG, S.A., and MARINCOLA, F.M. (1997). Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J. Sci. Am. 3, 37-44.
8. CROWLEY, N.J., VERVAERT, C.E., and SEIGLER, H.F. (1992). Human xenograft-nude mouse model of adoptive immunotherapy with human melanoma-specific cytotoxic T-cells. Cancer Res. 52, 394-399.
9. DARROW, T.L., SLINGLUFF, C.L., and SEIGLER, H.F. (1989). The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. J. Immunol. 142, 3329-3335.
10. ESSNER, R., RHOADES, K., McBRIDE, W.H., MORTON, D.L., and ECONOMOU, J.S. (1989). IL-4 down-regulates IL-1 and TNF expression in human monocytes. J. Immunol. 142, 3857-3861.
11. FABER, C., SANDT, G., DANG, P.T., MATGÉ, G., SCHILTZ, F., and HEUSCHLING, P. (1994). Interleukin-4 affects phenotype and proliferative response of peripheral blood lymphocytes from glioblastoma patients after specific or nonspecific in vitro stimulation. J. Immunother. 15, 113-118.
12. FERRONE, S., and MARINCOLA, F.M. (1995). Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance. Immunol. Today 16, 487-494.
13. FLEISCHHAUER, K., TANZARELLA, S., WALLNY, H., BORDIGNON, C., and TRAVERSARI, C. (1996). Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A0201 cytotoxic T cell line. J. Immunol. 157, 787-797.
14. GOLUMBEK, P.T., LAZENBY, A.J., LEVITSKY, H.I., JAFFEE, L.M., KARASUYAMA, H., BAKER, M., and PARDOLL, D.M. (1991). Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254, 713-716.
15. HARA, I., NGUYEN, H., TAKECHI, Y., GANSBACHER, B., CHAPMAN, P.B., and HOUGHTON, A.N. (1995). Rejection of mouse melanoma elicited by local secretion of interleukin-2: Implicating macrophages without T-cells or natural killer cells in tumor rejection. Int. J. Cancer 61, 253-260.
16. HOCK, H., DORSZCH, M., KUNZENDORF, U., QIN, Z., DIAMANTSTEIN, T., and BLANKENSTEIN, T. (1993). Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin-2, interleukin-4, interleukin-7, tumor necrosis factor, or interferon γ. Proc. Natl. Acad. Sci. U.S.A. 90, 2774-2778.
17. HOON, D., HAYASHI, Y., MORISAKI, T., FOSHAG, L.J., and MORTON, D.L. (1993). Interleukin-4 plus tumor necrosis factor α augments the antigenicity of melanoma cells. Cancer Immunol. Immunother. 37, 378-384.
18. KAWAKAMI, Y., ROSENBERG, S.A., and LOTZE, M.T. (1988). Interleukin-4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J. Exp. Med. 168, 2183-2191.
19. MAASS, G., SCHMIDT, W., BERGER, M., SCHILCHER, F., KOSZIK, F., SCHNEEBERGER, A., STINGL, G., BIRNSTIEL, M.L., and SCHWEIGHOFFER, T. (1995). Priming of tumor-specific T-cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: Three consecutive stages may be required for successful tumor vaccination. Proc. Natl. Acad. Sci. U.S.A. 92, 5540-5544.
20. MARGOLIN, K., ARONSON, F.R., SZNOL, M., ATKINS, M.B., GUCALP, R., FISHER, R.I., SUNDERLAND, M., DOROSHOW, J.H., ERNEST, M.L., MIER, J.W., DUTCHER, J.P., GAYNOR, E.R., and WEISS, G.R. (1994). Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. J. Immunother. 15, 147-153.
21. MARINCOLA, F.M., HIJAZI, Y., FETCH, P., SALGALLER, M.L., RIVOLTINI, L., CORMIER, J., KAWAKAMI, Y., and ROSENBERG, S.A. (1996). Analysis of tissue expression of the melanoma associated antigen MART-1 and GP-100 in metastatic melanoma. J. Immunother. 19, 192-205.
22. MELANI, C., SULÉ-SUSO-, J., ARIENTI, F., MACCALLI, C., PASSERINI, F., COLOMBO, M.P., and PARMIANI, G. (1995). A human melanoma cell line transduced with an interleukin-4 gene by a retroviral vector releases biologically active IL-4 and maintains the original tumor antigenic phenotype. Hum. Gene Ther. 6, 1427-1436.
23. MORTON, D.L., FOSHAG, L.J., HOON, D.S.B., NIZZE, J.A., WANEK, L.A., CHANG, C., DAVTYAN, D.G., GUPTA, R.K., ELASHOFF, R., and IRIE, R.F. (1992). Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. 216, 463-482.
24. NATALI, P.G., NICOTRA, M.R., BIGOTTI, A., VENTURO, I., MERCENARO, L., GIANCOMINI, P., and RUSSO, C. (1989). Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc. Natl. Acad. Sci. U.S.A. 86, 6719-6723.
25. NESTLE, O., ALIJAGIC, S., GILLIET, M., SUN, Y., GRABBE, S., DUMMER, R., BURG, G., and SCHADENDORF, D. (1998). Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Med. 4, 328-332.
26. PARDOLL, D.M. (1995). Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13, 399-415.
27. PARMIANI, G. (1998). Immunological approach to gene therapy of human cancer: Improvements through the understanding of mechanism(s). Gene Ther. 5, 863-864.
28. PARMIANI, G., COLOMBO, M.P., MELANI, C., and ARIENTI, F. (1996). Cytokine gene-transduction in the immunotherapy of cancer. Adv. Pharmacol. 40, 259-307.
29. PAUL, W.E. (1991). Interleukin-4: A prototypic immunoregulatory lymphokine. Blood 77, 1859-1870.
30. PAUL, W.E., and OHARA, J. (1987). B-cell stimulatory factor-1/interleukin 4. Annu. Rev. Immunol. 5, 429-459.
31. PERICLE, F., GIOVARELLI, M., COLOMBO, M.P., FERRARI, G., MUSIANI, P., MODESTI, A., CAVALLO, F., DI PIERRO, F., NOVELLI, F., and FORNI, G. (1994). An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J. Immunol. 153, 5659-5673.
32. REYNOLDS, S.R., CELIS, E., SETTE, A., ORATZ, R., SHAPIRO, R.L., JOHNSTON, D., FOTINO, M., and BYSTRYN, J.-C. (1998). HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. J. Immunol. 161, 6970-6976.
33. RIVOLTINI, L., KAWAKAMI, Y., SAKAGUCHI, K., SOUTHWOOD, S., SETTE, A., ROBBINS, P.F., MARINCOLA, F.M., SALGALLER, M.L., YANNELLI, J.R., APPELLA, E., and ROSENBERG, S.A. (1995). Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 154, 2257-2265.
34. RIVOLTINI, L., LOFTUS, D.J., BARRACCHINI, K., ARIENTI, P., MAZZOCCHI, A., BIDDISON, W.E., SALGALLER, M.L., APPELLA, E., PARMIANI, G., and MARINCOLA, F.M. (1996). Binding and presentation of peptides derived from melanoma antigens MART-1 and gp100 by HLA-A2 subtypes: Implications for peptide-based immunotherapy. J. Immunol. 156, 3882-3891.
35. ROSENBERG, S.A., YANG, J.C., SCHWARTZENTRUBER, D.J., HWU, P., MARINCOLA, F.M., TOPALIAN, S.L., RESTIFO, N.P., DUDLEY, M.E., SCHWARZ, S.L., SPIESS, P.J., WUNDERLICH, J.R., PARKHURST, M.R., KAWAKAMI, Y., SEIPP, C.A., EINHORN, J.H., and WHITE, D.E. (1998). Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4, 321-327.
36. SALLUSTO, F., and LANZAVECCHIA, A. (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte-macrophage colony stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 179, 1109-1118.
37. SCHWARTZENTRUBER, D.J., TOPALIAN, S.L., MANCINI, M., and ROSENBERG, S.A. (1991). Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-α, and IFN-γ by human tumor-infiltrating lymphocytes after autologous tumor stimulation. J. Immunol. 146, 3674-3681.
38. SIMONS, J.W., JAFFEE, E.M., WEBER, C.E., LEVITSKY, H.I., NELSON, W.G., CARDUCCI, M.A., LAZENBY, A.J., COHEN, L.K., FINN, C.C., CLIFT, S.M., HAUDA, K.M., BECK, L.A., LEIFERMAN, K.M., OWENS, A.H., PIANTADOSI, S., DRANOFF, G., MULLIGAN, R.C., PARDOLL, D.M., and MARCHALL, F.F. (1997). Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 57, 1537-1546.
39. STEVENS, E.J., JACKNIN, L., ROBBINS, P.F., KAWAKAMI, Y., EL-GAMIL, M., ROSENBERG, S.A., and YANNELLI, J.R. (1995). Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition. J. Immunol. 154, 762-771.
40. TARTOUR, E., BLAY, J.Y., DORVAL, T., ESCUDIER, B., MOSSERI, V., DOUILLARD, J.Y., DENEUX, L., GORIN, I., NEGRIER, S., MATHIOT, C., POUILLART, P., and FRIDMAN, W.H. (1996). Predictor of clinical response to interleukin-2 based immunotherapy in melanoma patients: A French multiinstitutional study. J. Clin. Oncol. 14, 1697-1703.
41. TEPPER, R.I., PATTENGALE, P.K., and LEDER, P. (1989). Murine interleukin-4 displays potent antitumor activity in vivo. Cell 57, 503-512.
42. TEPPER, R.I., COFFMAN, R., and LEDER, P. (1992). An eosinophil-dependent mechanism for the anti-tumor effect of interleukin-4. Science 257, 548-551.
43. THOMAS, M.C., GRETEN, T.F., PARDOLL, D.M., and JAFFE, E.M. (1998). Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum. Gene Ther. 9, 835-843.
44. UCHIYAMA, A., HOON, D.S.B., MORISAKI, T., KANEDA, Y., YUZUKI, D.H., and MORTON, D.L. (1993). Transfection of interleukin-2 gene into human melanoma cells augments cellular immune response. Cancer Res. 53, 949-952.
45. YANNELLI, J.R., HYATT, C., JOHNSON, S., HWU, P., and ROSENBERG, S.A. (1993). Characterization of human tumor cell lines transduced with the cDNA encoding either tumor necrosis factor α (TNF-α) or interleukin-2 (IL-2). J. Immunol. Methods 161, 77-90.